| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/14/2005 | WO2005062782A2 Non-animal product containing veterinary formulations |
| 07/14/2005 | WO2005062761A2 Stabilized prednisolone sodium phosphate solutions |
| 07/14/2005 | WO2005062722A2 Fexofenadine containing pharmaceutical formulation |
| 07/14/2005 | WO2005055972A3 A drug delivery device and a method of producing it |
| 07/14/2005 | WO2005053691A3 Nicotine delivery product and method for producing it |
| 07/14/2005 | WO2005051351A3 Gene delivery mediated by liposome-dna complex with cleavable peg surface modification |
| 07/14/2005 | WO2005044429A3 Reagent-containing membranes and laminates and methods of their prepration |
| 07/14/2005 | WO2005044175A3 Desensitization of complement activation using monocyte/macrophage inhibitory compounds |
| 07/14/2005 | WO2005041920A3 Pharmaceutical licofelone formulation |
| 07/14/2005 | WO2005037238A3 Chewing gum for the remineralisation of tooth enamel |
| 07/14/2005 | WO2005035779A3 Method |
| 07/14/2005 | WO2005034859A3 Extended release formulations of opioids and method of use thereof |
| 07/14/2005 | WO2005023929A3 Granule |
| 07/14/2005 | WO2005018623A8 Parenteral and oral formulations of benzimidazoles |
| 07/14/2005 | WO2005013935A3 Composition for releasing a weak base for an extended period of time |
| 07/14/2005 | WO2005009199A3 Process and machine for automated manufacture of gastro-retentive capsules |
| 07/14/2005 | WO2004105729A3 Transdermal vaccine delivery device having coated microprotrusions |
| 07/14/2005 | WO2004091537B1 Process for making gel films |
| 07/14/2005 | WO2004070546A3 Medical data communication notification and messaging system and method |
| 07/14/2005 | WO2004069179A3 Improved thickened beverages for dysphagia |
| 07/14/2005 | WO2004063024A3 Floral packaging material having prints thereon |
| 07/14/2005 | WO2004020969A3 Production of nanoparticles having a defined number of ligands |
| 07/14/2005 | US20050154374 Implantable sensors and implantable pumps and anti-scarring agents |
| 07/14/2005 | US20050154343 Soft tip applicator for relieving mouth pain |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154066 Antiaging composition |
| 07/14/2005 | US20050154057 Crystalline form of y-aminobutyric acid analog |
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154009 For example, (1R,2R,3S)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-3-(4-fluorophenyl)-tropane; use in treatment of neurodegenerative disorder with an associated cognitive deficit, such as Alzheimer's Disease, Lewis body disease, fronto-temporal dementia |
| 07/14/2005 | US20050154006 mixture of anticholinergic agents and pyridinecarboxamide's such as 2-(4-fluoro-phenoxy)-N-{4-(1-hydroxy-1-methyl-ethyl)-benzyl}nicotinamide in the form of enantiomers, racemates, solvates or hydrates and optionally mixed with excipients, used for treating respiratory system disorders |
| 07/14/2005 | US20050153994 The use of 5-fluorourcil, delivered by iontophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
| 07/14/2005 | US20050153982 Sustained release ranolazine formulations |
| 07/14/2005 | US20050153976 1-[(1-acetyl-4-piperidinyl)acetyl]-2(S)-(1,1-dimethylethyl)-4(S)*4-[phenyl [4(trifluoromethoxy)phenyl]methyl]piperazine; hydrophobic inhibitors of Type 3 17 beta -Hydroxysteroid Dehydrogenase and hydrophilic carrier; solubilizing drug; less toxicity and precipitation; stability over time |
| 07/14/2005 | US20050153967 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 07/14/2005 | US20050153956 Pharmaceutical compositions comprising midazolam in a high concentration |
| 07/14/2005 | US20050153949 Testosterone derivative |
| 07/14/2005 | US20050153948 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| 07/14/2005 | US20050153947 administering mixture of serotonine reuptake inhibitor and corticosteroid |
| 07/14/2005 | US20050153946 Water; antiinflammatory steroid and/or steroidal hormones, propylene glycol, polyethylene glycol, preservative,stabilizer; and buffer; concentration; seeding a crystal; forming heterogeneous mixture; heat resistance |
| 07/14/2005 | US20050153937 Administering encapsulated liposome nanoparticles of alendronate, pamidronate, clondronate, etidronate, tiludronate, gold, gallium, gadolinium, and/or selenium; treating hypersensitivity and/or complement activation-related pseudoallergy (CARPA) |
| 07/14/2005 | US20050153923 Receptor protein kinases (EphA2/EphA4); gene expression inhibition; rna interference; for treatment, management, or prevention of hyperproliferative cell disease/cancer |
| 07/14/2005 | US20050153920 Ribozymes used as prodrugs |
| 07/14/2005 | US20050153912 Antiviral oligonucleotides targeting viral families |
| 07/14/2005 | US20050153884 Methods of therapy with thrombin derived peptides |
| 07/14/2005 | US20050153862 oil absorbing polymer nanospheres coated with water sensitive surface active polymers; cosmetic, personal care, and household products to effectively encapsulate wide range of active ingredients and sensory markers and release them in response to moisture or over an extended period of time |
| 07/14/2005 | US20050153841 Injection formulation |
| 07/14/2005 | US20050153118 keratin, fibrin, collagen, or elastin from bird feathers; biodegradable polymer |
| 07/14/2005 | US20050153018 pellets comprising compacted inner matrices containing viable microorganisms and moisture barrier coatings |
| 07/14/2005 | US20050153001 Fenugreek seed extract to lower blood cholesterol |
| 07/14/2005 | US20050152999 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 07/14/2005 | US20050152983 micronized; directly compressible rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid; stable and bioavailable |
| 07/14/2005 | US20050152982 acceptable dissolution enhancer having a low concentration of carboxylic acid and ester substituents; relatively large amount of the drug can be delivered at a controlled rate over a relatively long period of time; reduces side-effect of diarrhea |
| 07/14/2005 | US20050152980 Pharmeutical microparticles |
| 07/14/2005 | US20050152978 Capsule, tablet with enteric, protective coatings; bioavailability |
| 07/14/2005 | US20050152977 Dosage form and method for producing the same |
| 07/14/2005 | US20050152976 Coated particles with prolonged release and tablets containing same |
| 07/14/2005 | US20050152975 Pharmaceutical composition |
| 07/14/2005 | US20050152974 once daily "pulsed" dosage form; first subunit comprises atomoxetine and a first release-retarding material and the second subunit comprises atomoxetine and a second release-retarding material |
| 07/14/2005 | US20050152973 Disintegrant |
| 07/14/2005 | US20050152972 disintegrates and dissolves slowly in the mouth to sooth the irritated area, and which is non-irritating to sensitive areas of the mouth |
| 07/14/2005 | US20050152971 Openings are provided in the dosage form that extend through the subcoat to the exterior surface of the elongated tablet or round tablet core in the exposed gap of the subcoatings |
| 07/14/2005 | US20050152970 Rapidly disintegrating gelatinous coated tablets |
| 07/14/2005 | US20050152969 Colored liquid-filled soft capsules and method of manufacture thereof |
| 07/14/2005 | US20050152968 Microemulsions for pharmaceutical compositions |
| 07/14/2005 | US20050152967 Comprises expectorant for immediate release and decongestant for extended release that provide for symptomatic relief of cough associated with respiratory tract conditions |
| 07/14/2005 | US20050152966 For controlled release of lyophilized probiotic bacterium; compressed tablets |
| 07/14/2005 | US20050152965 Combining a pharmaceutically active agent with a phospholipid, coating the combination with an acid-labile coating material; enhanced stability and bioavailability for pharmaceutical formulations |
| 07/14/2005 | US20050152964 Drug/lipid/polycation complexes; gene therapy |
| 07/14/2005 | US20050152963 Liposome compositions |
| 07/14/2005 | US20050152962 Composition for treatment of inflammatory disorders |
| 07/14/2005 | US20050152958 Ketoprofen patch delivery system |
| 07/14/2005 | US20050152957 Compositions and delivery systems for administration of a local anesthetic agent |
| 07/14/2005 | US20050152956 Therapy for sexual disorders |
| 07/14/2005 | US20050152951 Liquid, eye-instillable preparations comprising sodium hyaluronate |
| 07/14/2005 | US20050152949 Drug delivery to a joint |
| 07/14/2005 | US20050152948 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152947 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152946 Implantable sensors and implantable pumps and anti-scarring agents |
| 07/14/2005 | US20050152945 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152944 Breast, pectoral, chin, facial, lip, and nasal implants; inhibits angiogenesis and fibroblast migration; enzyme inhibitors |
| 07/14/2005 | US20050152941 Soft tissue implants and anti-scarring agents |
| 07/14/2005 | US20050152939 Delivery technology |
| 07/14/2005 | US20050152860 bone morphogenetic protein 4 (BMP-4) decreases melanin synthesis in melanocytes by decreasing the activity of tyrosinase |
| 07/14/2005 | US20050152856 0.5-7% by weight of D,L- alpha -lipoic acid, 0.05-0.5% by weight of coenzyme Q-10 and 0.01-3% by weight of acetyl-L-carnitine hydrochloride; treatment of visible sun injuries caused by processes involving the action of free radicals |
| 07/14/2005 | US20050152849 reduction in powder cohesion and adhesion improves the respirable fraction of the powder |
| 07/14/2005 | US20050152848 covalently coupling insulin to one or more molecules of a non-naturally occurring hydrophilic polymer such as polyethylene glycol; antidiabetic agents |
| 07/14/2005 | US20050152847 Novel formulation |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | US20050152845 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| 07/14/2005 | US20050152820 High temperature high pressure capsule for processing materials in supercritical fluids |
| 07/14/2005 | US20050150489 Dispensing medicaments based on rates of medicament action |
| 07/14/2005 | US20050150190 Packaging meterials for transdermal drug delivery systems |
| 07/14/2005 | DE202005006527U1 Dry galenic combination preparation for improving condition of joints, comprising rapid release glucosamine, chondroitin and copper and selenium salts and retarded release vitamins and minerals |
| 07/14/2005 | DE202004003241U1 Solubilized, high bioavailability vitamin product, comprising vitamin A (or its ester) and excess emulsifier, especially polysorbate 80 |
| 07/14/2005 | DE10358799A1 Verwendung von wasserdispergierbaren Copolymerisaten von Hydroxyalkyl(meth)acrylaten zur Herstellung von Hartkapseln Use of water-dispersible copolymers of hydroxyalkyl (meth) acrylates for the production of hard capsules |
| 07/14/2005 | DE10358749A1 Darreichungsform zur Bekämpfung von primären Kopfschmerzen Dosage form for the control of primary headaches |
| 07/14/2005 | DE10358748A1 Darreichungsform basierend auf vernetzten hydrophilen Polymeren Dosage form based on crosslinked hydrophilic polymers |
| 07/14/2005 | DE10357827A1 Preparing enzyme granules, useful in nutritional, cleaning and pharmaceutical compositions, by spraying enzyme solution into gas stream containing solid particles, followed by drying and granulation |
| 07/14/2005 | DE10356925A1 Inhalator für basische pharmazeutische Wirkstoffe sowie Verfahren für dessen Herstellung An inhaler for basic pharmaceutical agents, and methods for its preparation |